Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

Current Pathobiology Reports

Volumn 1, Issue 1, 2013, Pages 37-42

  Mortenson, Eric D ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adaptive immunity; Antibody therapies; Breast cancer; HER2 neu; Oncogenic signaling

Indexed keywords

EID: 84925295050     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-012-0001-8     Document Type: Review

References (48)

1. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147–1157
2. Griggs J, Zinkewich-Peotti K (2009) The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 101(11):1807–1812
3. Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316(7):1083–1100
4. Shih C, Padhy LC, Murray M, Weinberg RA (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290(5803):261–264
5. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28(4):865–871
6. Révillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34(6):791–808
7. Rajkumar T, Gullick WJ (1994) The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29(1):3–9
8. Shepard HM, Brdlik CM, Schreiber H (2008) Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118(11):3574–3581
9. Yarden Y, Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553–563
10. Quaglino E, Mastini C, Forni G, Cavallo F (2008) ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 82:20.9.1–20.9.10
11. Ménard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22(42):6570–6578
12. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (1985) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41(3):697–706
13. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9(3):1165–1172
14. Drebin JA, Link VC, Weinberg RA, Greene MI (1986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83(23):9129–9133
15. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A et al (1988) Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci USA 85(14):5102–5106
16. Eccles SA (2001) Monoclonal antibodies targeting cancer: “magic bullets” or just the trigger? Breast Cancer Res 3(2):86–90
17. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89(10):4285–4289
18. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138
19. Abramson V, Arteaga CL (2011) New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 17(5):952–958. doi:10.1158/1078-0432.CCR-09-1947
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344(11):783–792
21. Vogel C, Cobleigh M, Tripathy D, Gutheil J (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726
22. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648
23. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737–744
24. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
26. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
27. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446
28. Raja S, Luan H, Naramura M, Bailey T, Clubb R, Band V et al (2011) Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 10(1):28
29. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59(9):1295–1312
30. •• Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2):160–170.
31. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085):808–812
32. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57–63
33. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47–59
34. •• Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H et al (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108(17):7142–7147.
35. Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C et al (2012) Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. doi:10.1093/annonc/mds328
36. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6(5):383–393
37. Rosenberg SA (2005) The emergence of modern cancer immunotherapy. Ann Surg Oncol 12(5):344–346
38. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29(3):233–240
39. Ryschich E, Schmidt J, Hämmerling GJ, Klar E, Ganss R (2002) Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer 97(6):719–725
40. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14(1):28–36
41. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H et al (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201(5):779–791
42. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296
43. • Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237–251.
44. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183(3):725–729
45. Paul WE (ed) (1999) Fundamental immunology, 4th edn. Lippincott Williams & Wilkins, Philadelphia
46. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D et al (2012) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 122(3):1066–1075
47. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF et al (2007) Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179(3):1960–1968
48. Murphy CG, Morris PG (2012) Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23(8):765–776